Related Experiment Video

Updated: Aug 17, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Insulin-like growth factors I and II in children with systemic onset juvenile arthritis

A E Bennett1, E D Silverman, J J Miller

  • 1Department of Pediatrics, Stanford University Medical Center, CA.

The Journal of Rheumatology
|April 1, 1988
PubMed

Insights

Systemic juvenile arthritis (JA) is linked to growth failure in children. Insulin-like growth factor levels were low, but not directly correlated with reduced growth rates, especially during prednisone treatment.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Rheumatology

Background:

  • Systemic onset juvenile arthritis (JA) is associated with growth failure.
  • Growth hormone secretion is reportedly normal, but insulin-like growth factor (IGF) production in JA is not well-studied.

Purpose of the Study:

  • To measure serum concentrations of IGF-I and IGF-II in children with systemic JA.
  • To investigate the relationship between IGF levels, disease activity, and growth rates during different treatment regimens.

Main Methods:

  • Serum IGF-I and IGF-II levels were measured in children with systemic JA.
  • Measurements were taken at various times, including during treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) alone or with prednisone.

Main Results:

  • Mean IGF-I and IGF-II concentrations were below normal for age, irrespective of prednisone use.
  • Growth failure was observed during active disease periods in both treatment groups.
  • Lowest growth rates in individual children occurred during prednisone treatment, independent of IGF levels.

Conclusions:

  • Children with systemic JA exhibit reduced IGF-I and IGF-II levels.
  • Growth failure in systemic JA is not solely explained by IGF levels.
  • Prednisone treatment may negatively impact growth rates in children with systemic JA.

More Related Videos

A Pre-Clinical Model of Synovitis Using Ex vivo Human Synovial Tissue with Preserved Function and Architecture08:32

A Pre-Clinical Model of Synovitis Using Ex vivo Human Synovial Tissue with Preserved Function and Architecture

Published on: March 20, 2026

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.